The Pharmaceutical Product Life Cycle: Stages, Loss of Exclusivity and Life Cycle Management

FreeScore your brand plan before management does. Send me the scorecard

In more than twenty years of marketing medicines and consumer health brands in Egypt, Saudi Arabia and the GCC, I have seen the same pattern many times. A brand team works hard on the launch, enjoys the growth years, settles into maturity, and then discovers, about a year before generics arrive, that nobody owns the loss of exclusivity plan. By then the useful levers are closed, because they needed clinical work, regulatory approval or a new pack that takes years to prepare.

This guide explains the pharmaceutical product life cycle from a marketer’s point of view. It starts with the classic model, shows where a medicine’s life differs, explains loss of exclusivity versus patent expiry in plain language, and then spends most of its length on what a brand team actually does at each stage: the levers, the budget, the messages, the field force and the compliance limits. It closes with a planning checklist, a section on OTC and consumer health brands, and a fictional worked example with the arithmetic shown. If you are new to the industry, the Pharma marketing 101 guide gives the wider context first.

What Is the Product Life Cycle, and Where Does It Come From?

The idea is simple. When a product is introduced, sales grow slowly because few customers know it and distribution is thin. If it works, sales accelerate as more customers adopt it and competitors validate the category. Growth then slows as the market saturates, and the product enters maturity, where competition is about share rather than new users. Eventually something better or cheaper arrives and sales decline.

Levitt’s point in 1965 was that managers should use the curve to plan ahead: decide in advance what to do at each stage, rather than react once sales have already turned. Kotler’s Marketing Management textbook then attached typical strategies to each stage, such as building awareness at introduction, widening distribution in growth, defending share in maturity and harvesting or withdrawing in decline.

The concept has its critics. Nariman Dhalla and Sonia Yuspeh argued in a 1976 Harvard Business Review article, “Forget the product life cycle concept”, that many products do not follow the neat curve and that treating it as destiny can lead managers to abandon brands too early. That warning matters in pharma too. The curve is a planning frame, not a forecast. Your own data, market and competitors decide the actual shape.

Two other ideas help explain the launch part of the curve. Everett Rogers, in Diffusion of Innovations (1962), described how adoption spreads from innovators and early adopters to the majority. Frank Bass published a mathematical model of new product growth in 1969 that is still used in launch forecasting. In pharma, the “adopters” are first prescribers, then pharmacists and patients, which is why early experience among respected specialists matters so much.

How Is a Medicine’s Life Cycle Different From the Classic Model?

The pharmaceutical product life cycle has six stages that are worth separating, because each one asks different things of the brand team.

1. Development (before launch). Discovery, preclinical work and clinical trials, then the regulatory submission. This stage takes many years and produces no revenue. Patents are usually filed early in it, which means part of the patent term is used up before the product is even approved.
2. Pre-launch. The last two to three years before approval, when marketing builds the market understanding, the positioning, the evidence story and the launch plan. Promotion of an unapproved medicine is not allowed, so this is mostly work on insight, medical education through the medical function, and readiness.
3. Launch and uptake. The first months to years after approval, when the brand wins its first prescribers, formulary or tender listings and pharmacy availability. The shape of the launch curve in the first year or two often predicts where the brand will peak, which is why launch excellence gets so much attention.
4. Growth. Wider adoption, new indications if they are approved, more prescribers and more patients. Investment is usually at its highest here.
5. Maturity. Sales plateau. The brand competes with other branded medicines in the class, and the team shifts from winning new prescribers to keeping existing patients on therapy, defending access and improving profitability.
6. Loss of exclusivity and after. Generic copies (for small molecules) or biosimilars (for biologics) can be approved and sold. Prices and volumes come under pressure. The brand may continue for many years as an established product, often with a much smaller budget.

Three features make this different from a consumer product. First, the protected period is fixed in advance by law, so the end of exclusivity is a date the company can see coming years ahead. Second, the molecule usually outlives the brand: patients still need the treatment after LOE, they simply get it from a cheaper source. Third, almost every lever that could change the curve, from a new indication to a new pack, needs regulatory approval, which takes time. That is the reason LOE planning has to start early.

What Is the Difference Between Loss of Exclusivity and Patent Expiration?

Two separate systems protect a new medicine, and marketers often mix them up.

Patents are granted by a patent office and protect an invention: the molecule itself, a manufacturing process, a formulation, a specific use or a dosing method. Under the World Trade Organization’s TRIPS Agreement (1994), member countries must offer patent terms of at least 20 years from the filing date. Because the main patent is usually filed early in development, the time left after launch is much shorter than 20 years. A medicine can also be covered by several patents with different expiry dates, and any of them can be challenged in court or at the patent office.

Regulatory data protection and market exclusivity are granted under medicines law, not patent law. They stop a generic company from relying on the originator’s clinical trial data for a set period, or stop a copy from being marketed for a set period, whatever the patent position. TRIPS (Article 39.3) requires members to protect undisclosed test data submitted for marketing approval against unfair commercial use, but leaves the detail to each country. Two well-known systems show how different the detail can be:

• United States. The Drug Price Competition and Patent Term Restoration Act of 1984, known as Hatch-Waxman, created the abbreviated route for generic approval and, in return, gave originators a period of exclusivity for new chemical entities and some restoration of patent time lost during review. Biologics have their own pathway and exclusivity under the Biologics Price Competition and Innovation Act, passed in 2010.
• European Union. The system commonly called “8+2+1” gives eight years of data protection, a further two years of market protection, and a possible extra year for a significant new indication. Reform of the EU pharmaceutical rules has been under discussion, so check the version in force.

In Saudi Arabia and the GCC, the honest answer for a brand team is that the detail must come from your IP and regulatory counsel. Saudi Arabia is a WTO member and so is bound by the TRIPS requirements on patents and test data. Patents are handled by the Saudi Authority for Intellectual Property (SAIP), and medicines are registered by the SFDA. How long data protection lasts for a given product, and how patent status interacts with generic registration, should be confirmed product by product rather than assumed from another market. The rules vary by country across the GCC as well, so the LOE date for the same molecule can differ between Saudi Arabia, the UAE and Kuwait.

The practical rule: ask your IP, legal and regulatory colleagues for a written LOE date per country, with the protection that sets it and the risks that could move it. Then plan to that date. A brand plan that says “patent expires in 2029” without saying what else protects the product, and in which countries, is not an LOE plan.

What Does Marketing Do at Each Stage of the Pharmaceutical Life Cycle?

The table below gives the typical pattern for a prescription brand. It is a starting point, not a rule: a specialist medicine with a small prescriber base will look different from a primary care medicine with thousands of prescribers. The deeper planning work for each year sits in the pharma brand plan, and the choice of which prescribers and patients to focus on at each stage is covered in segmentation and targeting in pharma.

A few points from my own experience sit behind that table.

Pre-launch is where the curve is decided. The launch curve depends on decisions made before approval: which patient type to lead with, which prescribers to prioritise, how access will be secured and what the brand will stand for. The positioning work is covered in pharma brand positioning, and mapping where patients get stuck between symptom and treatment is covered in patient journey mapping. The whole launch sequence is in the guide to go-to-market strategy.

Launch needs focus more than volume. Spreading a launch budget across every prescriber produces a slow curve. Winning a defined group of early adopters first, then widening, follows the diffusion pattern Rogers described and usually produces a steeper start.

Maturity is where most money is quietly wasted. A mature brand often keeps its launch-sized field force and its launch messages out of habit. The patients who stop therapy early are often a larger opportunity than new prescribers, which shifts the work towards adherence, correct use and patient support within the rules.

After LOE, the question is which customers to keep. Some prescribers, patients and institutions value continuity, a familiar device or a support service enough to stay with the brand. Others will switch as soon as a cheaper option is available. The plan should name both groups rather than defend everyone.

Measuring progress in each stage needs different indicators: new prescribers and time to listing at launch, persistence and share in maturity, retained volume and contribution after LOE. The guide to pharma marketing KPIs covers how to choose them.

FreeScore your brand plan before management does. Send me the scorecard

What Are the Main Life Cycle Management Levers in Pharma?

Life cycle management sits close to what Igor Ansoff, in his 1957 Harvard Business Review article “Strategies for Diversification”, called product development (new products for existing markets) and market development (existing products for new markets). In pharma, both routes run through the regulator. The levers below are listed with the stage where they usually start and the main limit on each.

New indications

Adding an approved use for a new disease or patient group can widen the market and, in some systems, earn additional regulatory protection. It needs clinical evidence and an approved variation to the registration, so the work usually starts in the growth stage. The compliance limit is strict: a medicine may only be promoted for its approved indications in the country concerned. Talking about an indication before it is approved locally is off-label promotion, even if it is approved elsewhere. Scientific exchange on unapproved uses belongs to the medical function, not to sales materials.

New formulations and dosage forms

Extended-release versions, a once-daily form, an oral liquid for children, a new injection device or an easier-to-swallow tablet can solve a real patient problem and give prescribers a reason to stay with the brand. These need development work and regulatory approval, so they should start in maturity at the latest. The limit is twofold. Claims for the new form must be supported by evidence and approved; and moving patients to a new form purely to block generic substitution, without real patient benefit, has been criticised as “evergreening” and has drawn attention from competition authorities in some markets. The test I use: would a prescriber choose the new form if there were no generic coming?

Fixed-dose combinations

Combining two active ingredients in one tablet can reduce pill burden and support adherence, especially in chronic diseases where patients take several medicines. Combinations need their own registration and evidence that the combination is appropriate. The limit is clinical: a combination only helps patients who need both ingredients at those doses, and promotion must not suggest wider use than the approved indication.

Prescription-to-OTC switch

Where the regulator agrees that a medicine is safe for use without a prescription, a switch can open a new consumer market for the molecule. It changes almost everything: the decision-maker becomes the shopper and pharmacist, consumer advertising may become possible within approved claims, and the pack and leaflet must work for a layperson. A switch needs a regulatory application with evidence on safety in self-care and is not available for every molecule or in every country. Whether a switch is possible in Saudi Arabia for a given molecule is a question for the SFDA, not an assumption. The launch work for a new OTC product is covered in the guide to an OTC product launch in Saudi Arabia.

Authorised generics

An authorised generic is the originator’s own medicine sold without the brand name, either by the originator or by a partner under licence, usually at or near the time generics enter. It lets the originator keep part of the price-sensitive volume that would otherwise go to competitors. The limits are legal and regulatory: it needs its own registration in most markets, it can cannibalise the brand, and agreements between originators and generic companies around market entry have drawn antitrust scrutiny in the US and the EU. Legal review is not optional here.

Patient support programmes

Adherence support, injection training, nurse services, reminders and help with access can make a real difference to outcomes and to persistence on therapy. They usually start in growth and become more important in maturity and after LOE, when service is part of what distinguishes the brand. The limits are well defined in most codes: a programme must not act as an inducement to prescribe, must protect patient data under local privacy law, must report adverse events it hears about, and must not become a channel for promotion to patients of a prescription medicine. Run them through the medical and compliance functions, not only through marketing.

Pricing moves

In many markets the price of a prescription medicine is regulated, and in some, including Saudi Arabia, prices of registered medicines are set and published by the SFDA, while government procurement goes through NUPCO tenders. A brand’s price response at LOE is therefore partly a regulatory process, not just a commercial choice. For how regulated price setting works in Saudi Arabia, see this guide to Saudi drug pricing. The strategic side of price, including how to think about value and reference points, is covered in pharmaceutical pricing strategy. Thomas Nagle and Georg Müller’s The Strategy and Tactics of Pricing remains a useful reference for the principle that price should follow the value the customer sees, which after LOE often means accepting that some segments will no longer pay a brand premium.

How Should You Plan for Loss of Exclusivity Two to Three Years Ahead?

The checklist below is the one I would want any brand team to work through. Use it as a review at three years, two years and one year before the expected LOE date.

Three years before

• Confirm the LOE date in writing, per country. Ask IP, legal and regulatory for the protection that sets the date, the other protections in place, and any pending challenges that could move it.
• Map the competitors likely to enter. Which generic or biosimilar companies have registered or filed, in which countries, and with which forms? Your regulatory team can often see public registration information; the Saudi drug registration statistics guide shows the kind of data available.
• Choose the life cycle levers that can still be ready. Anything that needs clinical work or a new registration must be decided now. If it cannot be approved before LOE, it will not help.
• Understand how substitution works in each channel. Hospital tenders, private hospitals, chain pharmacies and independent pharmacies may each behave differently when a generic arrives. The Saudi pharmacy market statistics give context on the retail side.

Two years before

• Build an erosion forecast with scenarios. Volume and price after entry, by channel, in a low, central and high case. Base it on your market’s rules and any analogues you have from your own portfolio, not on another country’s numbers.
• Segment customers by likelihood to stay. Which prescribers, institutions and patient groups value something the generic will not offer (a device, a service, a familiar pack, supply reliability)? Which will switch on price alone?
• Decide the pricing scenario with regulatory input. Where prices are regulated, work through what the rules allow and when, before the business case assumes anything.
• Plan the resource shift. Field force size and deployment, promotional budget, medical support. A planned, gradual shift is kinder to people and to customers than a sudden cut after sales fall.
• Decide on an authorised generic, a partner or neither. This needs legal review and lead time for registration.

One year before

• Lock the supply plan. Over-stocking the trade before LOE creates returns and write-offs; under-supplying loyal customers loses them early.
• Prepare key account conversations. Tenders, hospital listings and chain agreements that renew around LOE need a position agreed in advance.
• Brief the field force honestly. Teams hear about LOE anyway. A clear plan keeps good people and keeps the message to customers consistent and compliant.
• Set post-LOE measures. Retained volume by segment, contribution margin, supply service level. Revenue alone will look like failure even when the plan works.
• Agree the plan across functions. Marketing, medical, regulatory, legal, supply chain and finance should sign the same document with the same date and the same assumptions.

What Does a Brand’s Revenue Curve Look Like Around Loss of Exclusivity?

Everything in this example is fictional and invented to show the method. “Brand A” and “Molecule X” do not exist, and the volumes, prices and costs are not benchmarks for any real market.

The situation. Brand A is a prescription medicine containing Molecule X. In the two years before LOE it sells 2,000,000 packs a year at SAR 50 a pack, so revenue is 2,000,000 × 50 = SAR 100 million a year. Cost of goods is SAR 10 a pack, so contribution before marketing and sales costs is (50 − 10) × 2,000,000 = SAR 80 million a year. Generics enter at the start of Year 1.

Scenario 1: no plan. The team keeps the price at SAR 50 and does nothing new. Volume falls to 900,000 packs in Year 1, 600,000 in Year 2 and 480,000 in Year 3.

Scenario 2: planned response. Two years ahead, the team prepared a lower price of SAR 40, approved through the applicable regulatory process (assumed here for illustration), and a patient support programme for its loyal segment costing SAR 2 million a year. Volume falls to 1,400,000 packs in Year 1, 1,200,000 in Year 2 and 1,100,000 in Year 3.

The arithmetic, line by line:

• Scenario 1 revenue: 900,000 × 50 = 45 million; 600,000 × 50 = 30 million; 480,000 × 50 = 24 million. Total 45 + 30 + 24 = SAR 99 million.
• Scenario 1 contribution at SAR 40 a pack (50 − 10): 900,000 × 40 = 36 million; 600,000 × 40 = 24 million; 480,000 × 40 = 19.2 million. Total 36 + 24 + 19.2 = SAR 79.2 million.
• Scenario 2 revenue: 1,400,000 × 40 = 56 million; 1,200,000 × 40 = 48 million; 1,100,000 × 40 = 44 million. Total 56 + 48 + 44 = SAR 148 million.
• Scenario 2 contribution at SAR 30 a pack (40 − 10), minus the SAR 2 million programme: 1,400,000 × 30 = 42, less 2 = 40 million; 1,200,000 × 30 = 36, less 2 = 34 million; 1,100,000 × 30 = 33, less 2 = 31 million. Total 40 + 34 + 31 = SAR 105 million.
• Difference over three years: revenue 148 − 99 = SAR 49 million in favour of the plan; contribution 105 − 79.2 = SAR 25.8 million in favour of the plan.

Two lessons come out of the example. First, the plan does not stop the decline: in both scenarios Brand A earns far less than the SAR 100 million a year it made before LOE. Second, the revenue gap (SAR 49 million) is almost twice the profit gap (SAR 25.8 million), because the lower price and the programme cost money. That is why LOE plans should be judged on contribution, not revenue. If you want to run the same kind of per-pack calculation for a consumer health brand, the contribution margin calculator does it, and the pharmacy trade margin calculator shows how trade margins sit between your price and the shelf price. To size the patient population behind a forecast like this, the patient-based market sizing calculator is a useful start.

How Does the Life Cycle Work for OTC and Consumer Health Brands?

An OTC painkiller, a vitamin range or a dermo-cosmetic cream can live for decades. There is no LOE date, but there is constant pressure: pharmacy private labels, new brands with sharper positioning, online sellers, and shoppers who drift to newer formats. A brand that does nothing slowly loses shelf space, pharmacist recommendation and relevance. That decline is quieter than an LOE cliff and easier to ignore, which makes it dangerous.

The main levers for a mature OTC or consumer health brand are:

• Brand refresh. New pack design, clearer symptom communication on the front of pack, updated brand identity and messaging, all within approved claims. A refresh should solve a problem you can name, such as poor shelf readability or a dated image with younger shoppers, not simply change the look.
• Line extensions. New formats (effervescent, liquid, spray, gummy where permitted), new strengths, new pack sizes or adjacent needs. Each needs registration in its category and shelf space, so add only variants with a clear role. Too many variants confuse the shopper and the pharmacist.
• New channels. E-pharmacy, marketplaces and, for products registered in a way that allows it, grocery and beauty retail. Each new channel brings reach and its own pricing and service demands.
• New occasions and segments. Reaching a new shopper group or a new moment of use, provided the registered indication and claims support it.
• Pharmacist recommendation. For OTC medicines in particular, sustained pharmacist education is often what keeps a mature brand recommended at the counter.
• Pruning. Withdrawing slow variants frees shelf space and focus for the ones that sell. Decline is not only managed by adding.

For OTC brands in Saudi Arabia, every pack change, claim and consumer advertisement needs to fit the SFDA’s rules for the product’s registration category, so refresh timelines must include review time. How the marketing mix changes between Rx, OTC and consumer health is covered in detail in the guide to the pharmaceutical marketing mix.

What Changes in Saudi Arabia and the GCC?

For a brand team in the region, the practical implications are:

• Every lever needs local approval. A new indication, formulation or switch approved in another country is not approved in Saudi Arabia until the SFDA approves it. Plan the local submission timeline, not the global one.
• Price is a process, not a lever you pull. Because the SFDA sets and publishes medicine prices, model price scenarios with your regulatory team and treat them as dependent on approval.
• The public sector matters. Where a large share of a molecule’s volume goes through NUPCO procurement, tender outcomes around LOE can move the curve more than any promotional activity.
• Dates differ by country. Patent status, data protection and generic registration timing can differ between Saudi Arabia and other GCC markets. A regional plan needs a country-by-country LOE table.
• Promotion rules stay in force through the whole life cycle. Prescription medicines cannot be promoted to the public at any stage, so patient support programmes and digital activity around LOE must stay within the rules.

Treat this section as a map of where to look rather than legal advice. Your regulatory and IP colleagues own the detail.

What Are the Most Common Life Cycle Mistakes in Pharma?

• Planning to the headline patent. The LOE date can be earlier or later than the main patent expiry. Get it in writing, per country.
• Starting the LOE plan a year before. By then most levers that need approval are out of reach.
• Treating life cycle management as a legal tactic. Levers that offer no real patient or prescriber benefit are unlikely to hold customers and can draw scrutiny. Build them on genuine needs.
• Defending everyone. After LOE, some customers will switch on price whatever you do. Spending to keep them wastes the budget needed for the customers who will stay.
• Judging the plan on revenue. As the worked example shows, a plan can look much better on revenue than on profit. Measure contribution.
• Keeping launch habits in maturity. A mature brand with a launch-sized field force and launch messages is usually overspending on the wrong work.
• Copying another market’s erosion curve. Substitution rules, pricing systems and channel structures differ. Forecast for your own market.
• Ignoring slow decline in OTC brands. No cliff does not mean no risk. Track shelf share, recommendation and distribution every year.

Key Takeaways

• A medicine follows the classic life cycle (Levitt, 1965) with a long pre-launch stage and a decline usually triggered by loss of exclusivity
• Loss of exclusivity is when every barrier to generic entry ends; it is not the same as patent expiry and can differ by country
• Life cycle levers include new indications, formulations, combinations, OTC switch, authorised generics, patient support and pricing, each with compliance limits
• Budget, messages, field force and channels should change with each stage, not stay at launch levels
• Start LOE planning two to three years ahead and judge the plan on contribution, not revenue
• In Saudi Arabia, the SFDA sets and publishes medicine prices and NUPCO handles government procurement, so price responses depend on regulatory processes
• OTC and consumer health brands have no patent cliff but still mature and decline; refresh, extend, prune and add channels

Frequently Asked Questions

What to Do Next

Take one brand you manage and write down three things on one page: its current life cycle stage, its LOE date per country with the protection that sets it (or, for an OTC brand, the main signs of maturity you can see in your data), and the levers that could still be ready before that date. If any of the three is blank, that is your first task this quarter.

Then bring the answers into your next brand plan. The structure for that document is in the guide to the pharma brand plan, and the wider picture of how the strategy fits together is in the cornerstone guide to pharma marketing strategy.